Recursion Pharmaceuticals to Release Q2 Earnings on Aug 4, Expecting $0.25 Loss per Share

Summary

Recursion Pharmaceuticals (RXRX) is set to report Q2 2026 earnings on August 4, with analysts forecasting a $0.25 loss per share and $10.97 million in revenue Market Beat+ 2. Despite beating EPS last quarter, the company missed revenue targets, and recent insider selling by CEO Najat Khan and Director Blake Borgeson has contributed to a cautious ‘Hold’ consensus among analysts Market Beat.

Impact Analysis

Recursion is heading into its August 4th print Market Beat at a precarious moment for AI-themed stocks. The market is currently rotating out of ‘AI promises’ and demanding realized cash flow, a sentiment shift triggered by recent Capex concerns at tech giants . For RXRX, the $10.97M revenue target Market Beat is the only number that matters; another miss here would suggest their AI-driven discovery platform isn’t gaining the commercial traction needed to offset a $0.25 per share burn Market Beat.

The ‘body language’ from management is also a concern. While institutional moves are mixed, seeing CEO Najat Khan and Director Blake Borgeson offloading shares Market Beat—even via 10b5-1 plans—right as the stock sits at a lukewarm $8.10 consensus target Market Beat feels defensive. I’d read this as a high-risk setup. If they can’t prove that their AI platform is shortening discovery timelines for partners now, the ‘AI-biotech’ premium will continue to deflate. I’m watching the revenue line closely—anything less than a beat likely triggers a sharp exit by remaining bulls.